Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica

View original at globenewswire.com
Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The probability of technical success for ADC monotherapies in Phase III is 53%, higher than the general oncology average

    80% confidence

  • A 160% increase in pancreatic cancer survival rates was reported in 2024 due to clinical trial advancements

    80% confidence

  • Global spending on cancer medicines reached USD 252 billion in 2024, reflecting a USD 29 billion increase from the previous year

    80% confidence

  • Biosimilars in oncology generated USD 7 billion in savings for payers in 2023/2024, with cumulative savings reaching USD 19 billion since 2017

    80% confidence

  • The number of oncology Novel Active Substances (NAS) launched globally in the 5-year period ending 2024 reached 132

    80% confidence

  • North America accounted for over 41.58% revenue share of the oncology clinical trials market

    80% confidence

  • Spending on cancer medicines will reach USD 441 billion by 2029

    80% confidence

  • Novel modalities, including ADCs and Cell/Gene therapies, accounted for 35% of all oncology trial starts in 2024

    80% confidence

  • The global oncology clinical trials market is projected to hit the market valuation of USD 25.61 billion by 2035 from USD 14.95 billion in 2025 at a CAGR of 5.53% during the forecast period 2026–2035

    80% confidence

  • Asia-Pacific is projected to witness the fastest CAGR from 2025 to 2034

    80% confidence

  • 2,162 oncology clinical trials were initiated globally in 2024, representing a 12-unit increase on an index basis compared to 2019 levels

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · drug approvals17 drugs
U.S. Food and Drug Administration · approval decisions32 decisions
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com